Compounded Tirzepatide Recall: How to Check Your Vial

If you use compounded tirzepatide, you have probably seen the recall headlines this week and wondered the same thing everyone else is wondering: is mine one of them?

Here is the short answer, and then the check you can do in about two minutes.

This recall is only for compounded tirzepatide made by Apothecary Pharma LLC in Cary, North Carolina. Brand names Mounjaro and Zepbound are not affected. It is not a recall of all compounded tirzepatide, and it is not a recall of every vial from this pharmacy. It is 22 specific lots.

The recall started September 24, 2026, and the FDA classified it as Class II on October 8, 2026. The reason given is a lack of assurance of sterility. That wording matters. It does not mean every vial in these lots is proven contaminated. It means the pharmacy could not assure that they were sterile, and for something you inject, that is enough to pull them.

How to check your vial

To see if you are impacted by the compounded tirezepatde recall by Apothecary Pharma, check your vial label for these four things, in this order:

1. Pharmacy name. This recall is Apothecary Pharma LLC only. If your vial came from a different pharmacy, it is not part of this recall.

2. Product. Tirzepatide Injection, 18 mg/mL, 4 mL sterile multi-dose vial, Rx only. The NDC is 85091-001-18.

3. Lot number. Compare it to the table below.

4. Beyond-use date. The dates below are the FDA-listed beyond-use dates for each lot.

If all four line up, your vial matches a recalled lot.

THE FULL RECALL DETAILS: Here's the FDA Detailed Report

The compounded tirezepatide recalled lots

Here are the 22 lots, with their beyond-use dates:

• AP-202622, beyond-use Oct 7, 2026

• AP-202623, beyond-use Oct 8, 2026

• AP-202624, beyond-use Oct 19, 2026

• AP-202625, beyond-use Oct 20, 2026

• AP-202627, beyond-use Oct 26, 2026

• AP-202628, beyond-use Oct 27, 2026

• AP-202629, beyond-use Oct 28, 2026

• AP-202630, beyond-use Oct 31, 2026

• AP-202631, beyond-use Nov 1, 2026

• AP-202632, beyond-use Nov 3, 2026

• AP-202633, beyond-use Nov 7, 2026

• AP-202634, beyond-use Nov 8, 2026

• AP-202635, beyond-use Nov 16, 2026

• AP-202636, beyond-use Nov 17, 2026

• AP-202637, beyond-use Nov 18, 2026

• AP-202638, beyond-use Nov 19, 2026

• AP-202639, beyond-use Nov 20, 2026

• AP-202640, beyond-use Nov 21, 2026

• AP-202641, beyond-use Nov 22, 2026

• AP-202642, beyond-use Nov 24, 2026

• AP-202643, beyond-use Nov 25, 2026

• AP-202644, beyond-use Nov 26, 2026

  
  

You will notice one number is missing on purpose. AP-202626 is not on the list. The sequence jumps from AP-202625 to AP-202627, so do not count it in just because it falls in the range.

The recall number is D-0036-2027, distribution was listed as nationwide, and the status is ongoing. You may also see 22 vials mentioned in some coverage. That is the FDA quantity field, a separate number from the 22 lots listed here. The FDA entry does not break it down by lot, so this post sticks to lots.

What to do if you are impacted by the compounded tirzepatide recall

Contact your dispensing pharmacy or prescriber before your next dose and ask for instructions for your specific vial.

Do not stop, swap, or change your medication on your own based on a blog post. That decision is yours and your clinician's. The safe step here is a phone call to the pharmacy that dispensed it, with your lot number in hand.

If your vial does not match, no action is needed from this recall. Keep the label until you finish the vial, as you normally would.

This Is Not Medical Advice

Please do not stop, swap, or change your medication on your own because of a blog post, including this one. That is a conversation for you and your clinician, with your actual vial in front of you.

A little background, because it will come up in other coverage: Apothecary Pharma was also the subject of a December 2025 FDA warning letter about sterile drug practices. That letter is separate from this recall, and the FDA has not said it caused this recall. No illnesses or injuries linked to this recall were identified in the coverage checked.

While generally we at GLP-1 Newsroom focus only on FDA-approved medications, this information was considered worth reporting since the reality is that at the price point these meds are set, many people seek more affordable compounded versions. At the root of our mission is the safety of every user. If you're using or considering a compounded version, it's worth reading the FDA's concerns and adverse use reports.